Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 299

1.

Selective side-chain modification of cysteine and arginine residues blocks pathogenic activity of HIV-1-Tat functional peptides.

Devadas K, Boykins RA, Hardegen NJ, Philp D, Kleinman HK, Osa EO, Wang J, Clouse KA, Wahl LM, Hewlett IK, Rappaport J, Yamada KM, Dhawan S.

Peptides. 2006 Apr;27(4):611-21. Epub 2005 Oct 26.

PMID:
16256245
2.

Antibodies against a multiple-peptide conjugate comprising chemically modified human immunodeficiency virus type-1 functional Tat peptides inhibit infection.

Devadas K, Boykins RA, Hewlett IK, Wood OL, Clouse KA, Yamada KM, Dhawan S.

Peptides. 2007 Mar;28(3):496-504. Epub 2006 Dec 22.

PMID:
17188401
3.

Cysteine-rich and basic domain HIV-1 Tat peptides inhibit angiogenesis and induce endothelial cell apoptosis.

Jia H, Lohr M, Jezequel S, Davis D, Shaikh S, Selwood D, Zachary I.

Biochem Biophys Res Commun. 2001 May 4;283(2):469-79. Erratum in: Biochem Biophys Res Commun 2001 Jun 1;284(1):245.

PMID:
11327725
4.
5.

Helper T-cell recognition of HIV-1 Tat synthetic peptides.

Blazevic V, Ranki A, Mattinen S, Valle SL, Koskimies S, Jung G, Krohn KJ.

J Acquir Immune Defic Syndr. 1993 Aug;6(8):881-90.

PMID:
7686223
6.

Inhibition of HIV-1 transcription and virus replication using soluble Tat peptide analogs.

Kashanchi F, Sadaie MR, Brady JN.

Virology. 1997 Jan 20;227(2):431-8.

7.

Activity of synthetic peptides from the Tat protein of human immunodeficiency virus type 1.

Frankel AD, Biancalana S, Hudson D.

Proc Natl Acad Sci U S A. 1989 Oct;86(19):7397-401.

8.

Cutting edge: a short polypeptide domain of HIV-1-Tat protein mediates pathogenesis.

Boykins RA, Mahieux R, Shankavaram UT, Gho YS, Lee SF, Hewlett IK, Wahl LM, Kleinman HK, Brady JN, Yamada KM, Dhawan S.

J Immunol. 1999 Jul 1;163(1):15-20.

9.

Structural variety of membrane permeable peptides.

Futaki S, Goto S, Suzuki T, Nakase I, Sugiura Y.

Curr Protein Pept Sci. 2003 Apr;4(2):87-96. Review.

PMID:
12678848
10.

Angiogenic potential in vivo by Kaposi's sarcoma cell-free supernatants and HIV-1 tat product: inhibition of KS-like lesions by tissue inhibitor of metalloproteinase-2.

Albini A, Fontanini G, Masiello L, Tacchetti C, Bigini D, Luzzi P, Noonan DM, Stetler-Stevenson WG.

AIDS. 1994 Sep;8(9):1237-44.

PMID:
7528513
11.

Recombinant human Fab antibody fragments to HIV-1 Rev and Tat regulatory proteins: direct selection from a combinatorial phage display library.

Pilkington GR, Duan L, Zhu M, Keil W, Pomerantz RJ.

Mol Immunol. 1996 Mar-Apr;33(4-5):439-50.

PMID:
8676895
12.

HIV-1 Tat protein mimicry of chemokines.

Albini A, Ferrini S, Benelli R, Sforzini S, Giunciuglio D, Aluigi MG, Proudfoot AE, Alouani S, Wells TN, Mariani G, Rabin RL, Farber JM, Noonan DM.

Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13153-8.

13.

Small HIV-1-Tat peptides inhibit HIV replication in cultured T-cells.

Löhr M, Kibler KV, Zachary I, Jeang KT, Selwood DL.

Biochem Biophys Res Commun. 2003 Jan 10;300(2):609-13.

PMID:
12504126
14.

B-cell epitopes in HIV-1 Tat and Rev proteins colocalize with T-cell epitopes and with functional domains.

Tähtinen M, Ranki A, Valle SL, Ovod V, Krohn K.

Biomed Pharmacother. 1997;51(10):480-7.

PMID:
9863510
15.

Important B-cell epitopes for neutralization of human immunodeficiency virus type 1 Tat in serum samples of humans and different animal species immunized with Tat protein or peptides.

Moreau E, Belliard G, Partidos CD, Pradezinsky F, Le Buanec H, Muller S, Desgranges C.

J Gen Virol. 2004 Oct;85(Pt 10):2893-901.

PMID:
15448351
16.
17.

Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1.

Viscidi RP, Mayur K, Lederman HM, Frankel AD.

Science. 1989 Dec 22;246(4937):1606-8.

PMID:
2556795
18.

Antibody spectrum against the viral transactivator protein in patients with human immunodeficiency virus type 1 infection and Kaposi's sarcoma.

Demirhan I, Chandra A, Mueller F, Mueller H, Biberfeld P, Hasselmayer O, Chandra P.

J Hum Virol. 2000 May-Jun;3(3):137-43.

PMID:
10881993
19.

Identification of HIV-1 Tat peptides for future therapeutic angiogenesis.

Ismail M, Henklein P, Huang X, Braumann C, Rückert RI, Dubiel W.

Eur J Haematol. 2006 Aug;77(2):157-65. Epub 2006 Jun 23.

PMID:
16800839
20.

Development of a functional backbone cyclic mimetic of the HIV-1 Tat arginine-rich motif.

Friedler A, Friedler D, Luedtke NW, Tor Y, Loyter A, Gilon C.

J Biol Chem. 2000 Aug 4;275(31):23783-9.

Supplemental Content

Support Center